Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.

OBJECTIVE Current pharmacologic treatments for a depressive episode in unipolar major depressive disorder (MDD) and bipolar depression are limited by low rates of remission. Residual symptoms include a persistent low mood and neurovegetative symptoms such as fatigue. The objective of this study was to examine the efficacy and tolerability of augmentation of first-line therapies with the novel stimulant-like agent modafinil in MDD and bipolar depression. DATA SOURCES MEDLINE/PubMed, PsycINFO, 1980-April 2013 were searched using the following terms: (modafinil or armodafinil) and (depressi* or depressed or major depressive disorder or major depression or unipolar or bipolar or dysthymi*). Inclusion criteria were as follows: randomized controlled trial (RCT) design, sample comprising adult patients (18-65 years) with unipolar or bipolar depression, diagnosis according to DSM-IV, ICD-10, or other well-recognized criteria, modafinil or armodafinil given as augmentation therapy in at least 1 arm of the trial, and publication in English in a peer-reviewed journal. STUDY SELECTION Double-blind, randomized, placebo-controlled clinical trials of adjunctive treatment with modafinil or armodafinil of standard treatment for depressive episodes in MDD and bipolar depression were selected. DATA EXTRACTION Two independent appraisers assessed the eligibility of the trials. A random-effects meta-analysis with DerSimonian-Laird method was used. Moderator effects were evaluated by meta-regression. RESULTS Data from 6 RCTs, with a total of 910 patients with MDD or bipolar depression, consisting of 4 MDD RCTs (n = 568) and 2 bipolar depression RCTs (n = 342) were analyzed. The meta-analysis revealed significant effects of modafinil on improvements in overall depression scores (point estimate = -0.35; 95% CI, -0.61 to -0.10) and remission rates (odds ratio = 1.61; 95% CI, 1.04 to 2.49). The treatment effects were evident in both MDD and bipolar depression, with no difference between disorders. Modafinil showed a significant positive effect on fatigue symptoms (95% CI, -0.42 to -0.05). The adverse events were no different from placebo. CONCLUSIONS Modafinil is an effective augmentation strategy for acute depressive episodes, including for symptoms of fatigue, in both unipolar and bipolar disorders.

[1]  T. Ketter,et al.  Use of adjunctive stimulants in adult bipolar depression. , 2013, The international journal of neuropsychopharmacology.

[2]  T. Robbins,et al.  Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers , 2013, Neuropharmacology.

[3]  Peter B. Jones,et al.  Effects of modafinil on cognitive functions in first episode psychosis , 2012, Psychopharmacology.

[4]  A. Harvey,et al.  Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance? , 2011, Journal of affective disorders.

[5]  S. Akhondzadeh,et al.  Double‐blind randomized parallel‐group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression , 2011, Depression and anxiety.

[6]  J. Calabrese,et al.  Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. , 2010, The Journal of clinical psychiatry.

[7]  B. Sahakian,et al.  The mental wealth of nations , 2008, Nature.

[8]  M. Brammer,et al.  Neuroanatomy of verbal working memory as a diagnostic biomarker for depression , 2008, Neuroreport.

[9]  M. Minzenberg,et al.  Modafinil: A Review of Neurochemical Actions and Effects on Cognition , 2008, Neuropsychopharmacology.

[10]  B. Candy,et al.  Psychostimulants for depression. , 2008, The Cochrane database of systematic reviews.

[11]  M. Brammer,et al.  Pattern Classification of Sad Facial Processing: Toward the Development of Neurobiological Markers in Depression , 2008, Biological Psychiatry.

[12]  L. Judd,et al.  Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. , 2008, Archives of general psychiatry.

[13]  S. Kennedy,et al.  Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. , 2008, The Journal of clinical psychiatry.

[14]  R. Gallop,et al.  Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study , 2007, Journal of clinical psychopharmacology.

[15]  John Suckling,et al.  A Longitudinal Functional Magnetic Resonance Imaging Study of Verbal Working Memory in Depression After Antidepressant Therapy , 2007, Biological Psychiatry.

[16]  Mark A Frye,et al.  A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. , 2007, The American journal of psychiatry.

[17]  M. Fava,et al.  Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. , 2007, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[18]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[19]  N. Atasoy,et al.  Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors , 2006, Advances in therapy.

[20]  M. Fava,et al.  Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study , 2006, CNS Spectrums.

[21]  M. Fava,et al.  A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. , 2005, The Journal of clinical psychiatry.

[22]  H. Solvason,et al.  A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression , 2004, Journal of clinical psychopharmacology.

[23]  F. Petty,et al.  Modafinil for Remitted Bipolar Depression with Hypersomnia , 2003, The Annals of pharmacotherapy.

[24]  R. Fieve,et al.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. , 2003, The Journal of clinical psychiatry.

[25]  R. Hirschfeld,et al.  Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. , 2003, The Journal of clinical psychiatry.

[26]  S. Hurt,et al.  Discontinuing or Switching Selective Serotonin-Reuptake Inhibitors , 2002, The Annals of pharmacotherapy.

[27]  K. Kaufman,et al.  Modafinil augmentation of antidepressant treatment in depression. , 2000, The Journal of clinical psychiatry.

[28]  J. Lépine,et al.  DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. , 1999, International clinical psychopharmacology.

[29]  John A. Rice,et al.  Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. , 1998, Journal of affective disorders.

[30]  R. Salamon,et al.  How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.

[31]  E Frank,et al.  Prodromal and residual symptoms in bipolar I disorder. , 1996, Comprehensive psychiatry.

[32]  R. Elliott,et al.  Cognitive Mechanisms of Treatment in Depression , 2012, Neuropsychopharmacology.

[33]  A. Yamatodani,et al.  Action of modafinil through histaminergic and orexinergic neurons. , 2012, Vitamins and hormones.

[34]  P. Masand,et al.  Psychostimulant augmentation of second generation antidepressants: A case series , 1998, Depression and anxiety.

[35]  M. Szuba,et al.  The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. , 1994, Psychopharmacology bulletin.